Skip to main content
    E

    Entrada Therapeutics Inc (TRDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.00
    -0.09 (-1.77%)

    Market Cap: $199.28M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Entrada Therapeutics Inc (TRDA) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Entrada Therapeutics (TRDA) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Entrada Therapeutics reported EPS of -$0.94, above the -$0.98 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    62%(13/21)
    Avg Surprise
    +5.46%
    Streak
    4 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.13
    Range-$1.85 - -$0.71
    9 analysts
    Revenue Consensus
    $7.62M
    RangeN/A
    9 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.73
    Range-$1.10 - -$0.12
    3 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.75+2.4%
    60d ago-$0.76+3.9%
    30d ago-$0.76+3.9%
    7d ago-$0.75+2.0%
    Current-$0.73
    Revenue Consensus
    $45.00M
    Range$45.00M - $45.00M
    1 analysts

    Next Report

    TRDA has an expected report date of Feb 24, 2027.

    Earnings History

    Of the 21 quarters below that had an estimate, TRDA beat 13 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $905000, down 43.8% from $1.61M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.94-$0.98-$1.22 - -$0.62+4.08%BeatN/A61 up, 1 downNov 5, 2026$905000
    Jun 30, 2026-$1.01-$1.16-$1.34 - -$0.68+12.93%BeatN/A73 up, 3 downAug 5, 2026$898000
    Mar 31, 2026-$0.95-$1.02-$1.16 - -$0.67+6.86%BeatN/A72 up, 2 downMay 7, 2026$875000
    Dec 31, 2025-$0.94-$1.32-$2.10 - -$0.60+28.79%Beat-3233.3%63 up, 1 downFeb 26, 2026$1.30M
    Sep 30, 2025-$1.06-$0.96-$1.13 - -$0.74-10.42%MissN/A40 up, 2 downNov 6, 2025$1.61M
    Jun 30, 2025-$1.04-$0.86-$0.98 - -$0.72-20.93%Miss-167.1%32 up, 1 downAug 6, 2025$1.95M
    Mar 31, 2025-$0.42-$0.77-$0.92 - -$0.70+45.45%Beat-161.8%40 up, 0 downMay 8, 2025$20.56M
    Dec 31, 2024$0.03-$0.67-$0.69 - -$0.62+104.48%BeatN/A52 up, 1 downFeb 27, 2025$37.40M
    Sep 30, 2024-$0.35-$0.62-$1.14 - -$0.47+43.55%Beat-134.3%50 up, 0 downNov 5, 2024$19.57M
    Jun 30, 2024$1.55$0.33-$0.41 - $0.77+369.70%BeatN/A40 up, 0 downAug 13, 2024$94.69M
    Mar 31, 2024$0.68-$0.47-$1.10 - -$0.01+244.68%BeatN/A50 up, 0 downMay 7, 2024$59.12M
    Dec 31, 2023-$0.29-$0.17-$0.53 - $0.21-70.59%MissN/A50 up, 0 downMar 13, 2024$41.85M
    Sep 30, 2023$1.02-$0.63-$1.04 - -$0.39+261.90%BeatN/A40 up, 0 downNov 7, 2023$43.73M
    Jun 30, 2023-$0.78-$0.60-$0.96 - -$0.23-30.00%MissN/A40 up, 0 downAug 8, 2023$18.17M
    Mar 31, 2023-$0.21-$0.84-$0.84 - $5.97+75.00%BeatN/A41 up, 0 downMay 10, 2023$25.26M
    Dec 31, 2022-$0.79-$0.83-$0.84 - -$0.82+4.82%BeatN/A30 up, 0 downMar 6, 2023N/A
    Sep 30, 2022-$0.80-$0.77-$0.77 - -$0.75-3.90%MissN/A20 up, 0 downNov 7, 2022N/A
    Jun 30, 2022-$0.74-$0.73N/A-1.37%MissN/AN/A0 up, 0 downAug 11, 2022N/A
    Mar 31, 2022-$0.69-$0.65-$0.66 - -$0.65-6.15%MissN/A20 up, 0 downMay 12, 2022N/A
    Dec 31, 2021-$0.89-$1.28-$1.85 - -$0.72+30.47%BeatN/A20 up, 0 downMar 15, 2022N/A
    Sep 30, 2021-$9.78-$0.91-$0.91 - -$0.83-974.73%MissN/A20 up, 0 downNov 1, 2021N/A
    Jun 30, 2021-$0.45N/AN/AN/AN/AN/AN/AN/ASep 1, 2021N/A
    Mar 31, 2021-$7.08N/AN/AN/AN/AN/AN/AN/AJun 30, 2021N/A
    Dec 31, 2020-$7.08N/AN/AN/AN/AN/AN/AN/AMar 31, 2021N/A
    Mar 31, 2020-$5.18N/AN/AN/AN/AN/AN/AN/AJun 29, 2020N/A
    Dec 31, 2019-$5.18N/AN/AN/AN/AN/AN/AN/AMar 30, 2020N/A
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.46, after $1.91 the year before. It was -$5.18 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.46-281.2%
    Dec 31, 2024$1.91N/A
    Dec 31, 2023-$0.26N/A
    Dec 31, 2022-$3.02N/A
    Dec 31, 2021-$18.20N/A
    Dec 31, 2020-$12.26N/A
    Dec 31, 2019-$5.18N/A

    Frequently Asked Questions About TRDA

    When is Entrada Therapeutics's next earnings date?

    Entrada Therapeutics's next earnings report is expected for Feb 24, 2027.

    Did TRDA beat earnings estimates last quarter?

    Yes. Entrada Therapeutics reported EPS of -$0.94 for the quarter ended Sep 30, 2026, above the -$0.98 estimate, a 4.08% surprise.

    What EPS do analysts expect from TRDA next quarter?

    The consensus EPS estimate for Entrada Therapeutics for the quarter ending Dec 31, 2026 is -$1.13 from 9 analysts, with estimates from -$1.85 to -$0.71.

    How often does TRDA beat earnings estimates?

    Entrada Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +21.41%.